利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.029 秒)

    Method of Treating Cachexia and Sarcopenia
    3.
    发明申请
    Method of Treating Cachexia and Sarcopenia 审中-公开
    治疗恶病质和症状的方法

    公开(公告)号：US20140194484A1

    公开(公告)日：2014-07-10

    申请号：US14101272

    申请日：2013-12-09

    申请人： Andrew Coats ,  John Beadle ,  Stefan Anker

    发明人： Andrew Coats ,  John Beadle ,  Stefan Anker

    IPC分类号： A61K31/404

    CPC分类号： A61K31/404 ,  A61K9/2018 ,  A61K9/205

    摘要： The present invention relates to a method of treating a cachexia and/or sarcopenia with an oral dose of S-pindolol or a pharmaceutical formulation thereof and to an oral formulation for use in said method of treatment. The method and oral formulation comprise administering a total daily dose of 2.5 to 20 mg of S-pindolol or a pharmaceutical formulation comprising the same.

    摘要翻译： 本发明涉及用口服剂量的S-哌哚洛尔或其药物制剂和用于所述治疗方法的口服制剂治疗恶病质和/或肌营养不良的方法。 该方法和口服制剂包括施用2.5至20mg的S-日吲哚的总日剂量或包含其的药物制剂。

    OXPRENOLOL COMPOSITIONS FOR TREATING CANCER
    4.
    发明申请
    OXPRENOLOL COMPOSITIONS FOR TREATING CANCER 审中-公开
    用于治疗癌症的OXPRENOLOL组合物

    公开(公告)号：US20160022612A1

    公开(公告)日：2016-01-28

    申请号：US14776020

    申请日：2014-03-14

    申请人： Andrew J.S. Coats ,  Stefan Anker ,  Jochen Springer

    发明人： Andrew J.S. Coats ,  Stefan Anker ,  Jochen Springer

    IPC分类号： A61K31/138

    CPC分类号： A61K31/138

    摘要： The present invention relates to compositions of S-enantiomer enriched oxprenolol and their use in treating cancer and treating or preventing, in cancer patients, cachexia, body weight loss, lean body mass loss and adipose tissue loss, and improving quality of life and prolonging survival of cancer patients.

    摘要翻译： 本发明涉及S-对映异构体富含氧吗啡洛尔的组合物及其在治疗癌症中的用途，并且在癌症患者中治疗或预防恶病质，体重减轻，瘦体重减少和脂肪组织损失以及改善生活质量和延长生存期 的癌症患者。

    THERAPY AND USE OF COMPOUNDS IN THERAPY
    6.
    发明申请
    THERAPY AND USE OF COMPOUNDS IN THERAPY 审中-公开
    治疗方法和化疗方法的使用

    公开(公告)号：US20090197851A1

    公开(公告)日：2009-08-06

    申请号：US12187169

    申请日：2008-08-06

    申请人： Stefan Anker ,  Andrew Coats ,  Hans-Dieter Volk ,  Mathias Rauchhaus ,  Ralf Reiner Schumann

    发明人： Stefan Anker ,  Andrew Coats ,  Hans-Dieter Volk ,  Mathias Rauchhaus ,  Ralf Reiner Schumann

    IPC分类号： A61K31/575 ,  A61P9/00

    CPC分类号： A61K31/575

    摘要： A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation. A method of treating, preventing or ameliorating endotoxin-mediated immune activation in acute or chronic heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation.

    摘要翻译： 一种治疗，预防或改善患者的慢性心力衰竭或急性心力衰竭的方法，该方法包括向患者施用有效量的：能够结合内毒素（脂多糖; LPS）分子的化合物，例如LPS 结合蛋白质，BPI，脂蛋白，胆汁酸或能够结合LPS的抗体，能够结合肠中的内毒素（脂多糖; LPS）分子或细菌的化合物，例如活性炭，胆汁酸或富勒氏土， 在肠道中基本上具有活性的抗菌剂，能够抑制细胞对内毒素（脂多糖; LPS）的反应的试剂，可能形成屏障或另外阻碍细菌或内毒素（LPS）易位的药剂， 从肠道到患者的流通。 一种在患者急性或慢性心力衰竭中治疗，预防或改善内毒素介导的免疫激活的方法，该方法包括向患者施用有效量的：能够结合内毒素（脂多糖; LPS）分子的化合物 ，例如LPS结合蛋白，BPI，脂蛋白，胆汁酸或能够结合LPS的抗体，能够结合肠中的内毒素（脂多糖; LPS）分子或细菌的化合物，例如活性炭，胆汁酸 或富勒的地球，在肠中基本上具有活性的抗菌剂，能够抑制细胞对内毒素（脂多糖; LPS）的反应的试剂，可能形成屏障或以其它方式阻碍细菌易位的药剂或 内毒素（LPS）从肠道进入患者的循环。

    Therapy and Use of Compounds in Therapy
    7.
    发明申请
    Therapy and Use of Compounds in Therapy 审中-公开
    治疗和化合物在治疗中的应用

    公开(公告)号：US20070197485A1

    公开(公告)日：2007-08-23

    申请号：US11627183

    申请日：2007-01-25

    申请人： Stefan Anker ,  Andrew Coats ,  Hans-Dieter Volk ,  Ralf Schuman ,  Mathias Plauth ,  Herbert Lochs

    发明人： Stefan Anker ,  Andrew Coats ,  Hans-Dieter Volk ,  Ralf Schuman ,  Mathias Plauth ,  Herbert Lochs

    IPC分类号： A61K31/56

    CPC分类号： A61K31/575

    摘要： A method for treating cachecia, liver disease, and other wasting syndromes is provided. The treatment method comprises administering a therapeutically effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin. Examples of such compounds include, but are not limited to, bile acids; bactericidal/permeability increasing proteins; lipoproteins; antibodies capable of binding to endotoxins; LPS binding protein; activated charcoal, Fuller's earth, attapulgite, kaolin or bentonite or a clay; a drug blocking effectively signaling through toll-like receptors; and calostrum or human, bovine or other mammals.

    摘要翻译： 提供了一种治疗缓解期，肝病和其他消瘦综合征的方法。 治疗方法包括施用治疗有效量的能够降低内毒素的产生，吸收和/或作用的化合物。 这些化合物的实例包括但不限于胆汁酸; 杀菌/渗透性增加蛋白质; 脂蛋白; 能够结合内毒素的抗体; LPS结合蛋白; 活性炭，富勒土，绿坡缕石，高岭土或膨润土或粘土; 药物阻断通过收费样受体有效发信号; 和饮水或人，牛或其他哺乳动物。

    METHOD FOR ENHANCING THE PERFORMANCE AND GENERAL CONDITION OF A SUBJECT
    9.
    发明申请
    METHOD FOR ENHANCING THE PERFORMANCE AND GENERAL CONDITION OF A SUBJECT 有权
    提高主体性能和一般条件的方法

    公开(公告)号：US20090248101A1

    公开(公告)日：2009-10-01

    申请号：US12088466

    申请日：2006-09-28

    申请人： Stefan Anker

    发明人： Stefan Anker

    IPC分类号： A61N1/362 ,  A61N1/39

    CPC分类号： A61N1/05 ,  A61B5/0464 ,  A61N1/362 ,  A61N1/3962

    摘要： The invention concerns the therapy with a cardiac resynchronisation device (CRT) and/or therapy with an automated internal cardiac defibrilator (ICD) for the treatment of subjects without cardiac diseases, in particular patients with any cancer or patients with cachexia due to acute or chronic illness other than cardiac illness, including malignant tumor disease, COPD, chronic renal failure, liver cirrhosis, chronic infections, and/or AIDS.The invention is implemented by a method comprising the connection of the heart of the subject with a cardiac pacemaker, in particular to reduce symptoms of shortness of breath, weakness and fatigue, and/or to reduce and/or reverse weight loss and/or to reduce and/or to reverse muscle wasting, and/or to improve general quality of life, and/or to reduce hospitalization length or rate or frequency, and/or to reduce cause-specific mortality, and/or to reduce total mortality, and/or to improve any combined endpoint of the above, and/or to improve compliance to cancer therapy, particularly chemotherapy and radiation therapy.

    摘要翻译： 本发明涉及用心脏再同步装置（CRT）和/或用自动内部心脏去纤颤器（ICD）进行治疗的治疗，用于治疗无心脏疾病的受试者，特别是患有任何癌症或由于急性或慢性的恶病质患者 心脏疾病以外的疾病，包括恶性肿瘤疾病，COPD，慢性肾功能衰竭，肝硬化，慢性感染和/或艾滋病。 本发明通过包括使受试者的心脏与心脏起搏器相连的方法实现，特别是减少呼吸短促，虚弱和疲劳的症状，和/或减轻和/或逆转体重减轻和/或 和/或改善一般生活质量，和/或减少住院时间，速率或频率，和/或减少原因特异性死亡率和/或降低总死亡率;以及 /或改善上述的任何组合终点，和/或改善对癌症治疗，尤其是化疗和放射治疗的依从性。